Financial Data and Key Metrics Changes - Q4 revenue was $109.7 million, up 15% year over year [10] - Q4 adjusted EBITDA was $16.4 million, reflecting a significant increase from the previous year [10] - Q4 average healthcare services clients reached $4,341, an increase of $104 from the prior quarter and $379 from the prior year [10] - Q4 total revenue per AhSE was $25,266, up 5% year over year [10] - Q4 operating cash flow was positive at $16.3 million, up $19.3 million year over year [10] - Q4 free cash flow was positive at $9.2 million, up $20.1 million year over year [10] - Cash position improved to $84.2 million as of January 31, up $2.5 million from October 31, 2024 [11] Business Line Data and Key Metrics Changes - The Appresia platform was used in approximately 14% of patient visits across the United States, equating to around 170 million sites [9] - Strong growth was noted in network solutions, with expectations for similar market conditions in 2026 as in 2025 [18][19] Market Data and Key Metrics Changes - The company is monitoring macroeconomic factors closely, including consumer confidence and Medicaid changes, but has not seen significant impacts on business as of now [66][68] Company Strategy and Development Direction - The company aims to continue generating positive free cash flow while investing in long-term profitable revenue growth [11] - The revenue outlook for fiscal year 2026 is maintained at a range of $472 million to $482 million, with adjusted EBITDA expected between $78 million and $88 million [12] - The company is focused on leveraging AI and automation to improve productivity and drive business growth [32][34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in maintaining growth despite potential macroeconomic challenges, emphasizing a strong operational foundation [66][70] - The company is committed to capital allocation strategies that prioritize durable and profitable growth, considering both organic and inorganic opportunities [70][72] Other Important Information - The company has not made any acquisitions in fiscal year 2025, but previous acquisitions are contributing to growth [75] - The company is excited about the rollout of new products that enhance patient engagement and medication adherence [8][49] Q&A Session Summary Question: What is the potential for gross margin expansion? - Management indicated that mix is a significant driver of gross margin, with expectations for higher growth in certain revenue lines contributing to expansion [16][18] Question: How are market conditions expected to change in 2026? - Management expects market conditions in 2026 to be similar to those in 2025 [19] Question: Can you explain the postscript engagement product? - The product operates on an impression-based model, leveraging data to remind patients about prescriptions [24][25] Question: What impact did the calendar have on revenue per AhSE? - Management noted that calendar factors, including holidays and weather, significantly impacted Q4 performance [30] Question: What progress has been made in leveraging AI? - Management reported positive real-time impacts from AI applications, particularly in forecasting and productivity improvements [34] Question: How is the company positioned in the competitive landscape? - Management noted improved close rates and a beneficial position as a market leader amidst new entrants [42] Question: What is the strategy for capital deployment in 2026? - The company will continue to prioritize capital allocation for durable growth, considering both organic and inorganic opportunities [70][72]